



CS/NSE/BSE/UFR/2013-14
February 4, 2014

TO
THE MANAGER
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LTD
EXCHANGE PLAZA, BANDRA- KURLA
COMPLEX, BANDRA (E), MUMBAI-400 051

Stock Code - SUVEN EQ

TO
THE GENERAL MANAGER
DEPARTMENT OF CORPORATE SERVICES
BOMBAY STOCK EXCHANGE LTD
25TH FLOOR, P. J. TOWERS,
DALAL STREET, MUMBAI - 400 001

Stock Code - 530239

Dear Sir/Madam,


Sub: Notification of Un-audited Financial Results for the quarter ended December 31, 2013 – Clause 41

.....

With reference to the above subject, we are forwarding here with **Un-audited Financial Results of our Company for three/ nine months ended 31st December, 2013** in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the third quarter in its meeting held on 04th February, 2014 and **Limited Review Report of Auditors of the Company**.

Please find enclosed Press release of our company. We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**


K. HANUMANTHA RAO
Company Secretary

SUVEN LIFE SCIENCES LIMITED

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: info@suven.com, www.suven.com

News Release

Suven Q3 PAT up by 370% to Rs.36.43 Cr

HYDERABAD, INDIA (4 Feb' 2014) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services (CRAMS) company today announced its un-audited financial results for the quarter ended 31st Dec 2013. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 4th Feb 2014 at Hyderabad.

Financial Highlights for the 3rd Quarter ended Dec' 2013:

Growth in revenue	Rs 1203 Mn vs.Rs 628 Mn	- Up by 92%
Growth in PAT	Rs 364 Mn vs. Rs 78 Mn	- Up by 370%
Growth in EBIDTA	Rs 557 Mn vs. Rs 152 Mn	- Up by 266%

Financial Highlights for the 9 months period ended Dec' 2013:

Growth in revenue	Rs 3836 Mn vs.Rs 1837 Mn	- Up by 109%
Growth in PAT	Rs 1118 Mn vs. Rs 222 Mn	- Up by 403%
Growth in EBIDTA	Rs 1734 Mn vs. Rs 401 Mn	- Up by 333%

The growth in profit was a result of prelaunch supplies of 3 products under CRAMS.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 356 Mn (9.27% on revenue) for the Nine months period ended Dec ' 2013 for the accounting year 2013-14.

SUVN-502 undergoing phase 1b clinical trial in USA.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

SUVEN LIFE SCIENCES LIMITED

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: info@suven.com, www.suven.com